301 filings
8-K
OGEN
Oragenics Inc
20 Jun 24
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
8:00am
8-K
OGEN
Oragenics Inc
23 May 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9:27am
8-K
OGEN
Oragenics Inc
22 May 24
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
8:00am
8-K
OGEN
Oragenics Inc
17 May 24
Other Events
8:00am
8-K
OGEN
Oragenics Inc
16 May 24
Other Events
8:00am
8-K
7j2gvo5h6jamndtlq2ig
7 May 24
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
8:14am
8-K
ktvzvaczp1wz9lzy o1
19 Apr 24
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
5:48pm
8-K
y5g3ry61k9 r4danu
15 Apr 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:01pm
8-K
ts89cwun1d
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
8-K
ad1hxe
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
8-K
u5r3d bgj
28 Feb 24
Oragenics Announces Pricing of Public Offering
9:03am
8-K
iazxfvnzj1
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
8-K
1mw36i3 ik9mwzo6
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
odj7z9 weamsjp1o5uz1
7 Feb 24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
8:00am
8-K
bm0bw
5 Feb 24
Other Events
8:00am
8-K
kprxcyrmmjz73za60at
23 Jan 24
Oragenics Announces Termination of At-The-Market Offering Program
5:18pm
8-K
6ix 5u078zh7d7nmzwsh
16 Jan 24
Other Events
9:10am
8-K
w6ie5vp24 ukt87e8b9
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
7bggtf0v
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
tqensq8 p7t
15 Dec 23
Material Modifications to Rights of Security Holders
3:45pm